Upward Trajectory: ARS Pharmaceuticals Inc (SPRY) Posts a Gaine, Closing at 14.19

Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The closing price of ARS Pharmaceuticals Inc (NASDAQ: SPRY) was $14.19 for the day, up 1.36% from the previous closing price of $14.00. In other words, the price has increased by $1.36 from its previous closing price. On the day, 0.68 million shares were traded. SPRY stock price reached its highest trading level at $14.39 during the session, while it also had its lowest trading level at $13.85.

Ratios:

Our analysis of SPRY’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 32.78 and its Current Ratio is at 32.78. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

On August 13, 2024, Raymond James Upgraded its rating to Strong Buy which previously was Outperform and also upped its target price recommendation from $18 to $22.

Leerink Partners reiterated its Outperform rating for the stock on August 12, 2024, while the target price for the stock was revised from $19 to $20.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 18 ’24 when Karas Eric sold 10,000 shares for $14.00 per share. The transaction valued at 140,000 led to the insider holds 5,693 shares of the business.

Tanimoto Sarina sold 100,000 shares of SPRY for $1,293,205 on Sep 17 ’24. The CHIEF MEDICAL OFFICER now owns 1,398,499 shares after completing the transaction at $12.93 per share. On Sep 17 ’24, another insider, Lowenthal Richard E, who serves as the PRESIDENT AND CEO of the company, sold 100,000 shares for $12.93 each. As a result, the insider received 1,293,205 and left with 1,398,499 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SPRY now has a Market Capitalization of 1375601280 and an Enterprise Value of 1157017472. For the stock, the TTM Price-to-Sale (P/S) ratio is 2751.16 while its Price-to-Book (P/B) ratio in mrq is 6.39. Its current Enterprise Value per Revenue stands at 2314.035 whereas that against EBITDA is -20.415.

Stock Price History:

Over the past 52 weeks, SPRY has reached a high of $16.50, while it has fallen to a 52-week low of $3.35. The 50-Day Moving Average of the stock is 12.69%, while the 200-Day Moving Average is calculated to be 52.09%.

Shares Statistics:

SPRY traded an average of 1.11M shares per day over the past three months and 903980 shares per day over the past ten days. A total of 96.41M shares are outstanding, with a floating share count of 48.91M. Insiders hold about 49.55% of the company’s shares, while institutions hold 38.58% stake in the company. Shares short for SPRY as of 1726185600 were 11637226 with a Short Ratio of 10.49, compared to 1723680000 on 12065892. Therefore, it implies a Short% of Shares Outstanding of 11637226 and a Short% of Float of 22.620001000000002.

Most Popular